A Phase 3 interventional study of Engasertib and Placebo in Hereditary Hemorrhagic Telangiectasia, sponsored by Vaderis Therapeutics AG. Recruiting at 17 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Vaderis Therapeutics AG · Phase 3, Interventional, and Treatment
Belgium, France, Germany, Hungary, Italy, Netherlands, Spain, United Kingdom
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Telangiectasia, Hereditary Hemorrhagic · United States.
Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 29th registered.
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
Browse Telangiectasia, Hereditary Hemorrhagic studies →5 of the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States are open now. Recruiting first, the newest first:
Ashley Nelson · Sites in United States
Ages 2–25
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Cure HHT · Sites in United States
Healthy volunteers
Columbia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 2 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 33 across 61 interventional studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Median enrollment 27 across the 20 interventional studies, 223 across the 9 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
Vaderis Therapeutics AG is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Vaderis Therapeutics AG has 2 studies filed under Telangiectasia, Hereditary Hemorrhagic — fewer than ten, so there is no comparison to draw.
2 of the studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07474428Ashley NelsonQuality of Life in Pediatric Participants With HHT | 2026-12 |
| NCT05406362Vaderis Therapeutics AGAssess Safety and Efficacy of VAD044 in HHT Patients | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants have a definite diagnosis of HHT by the Curaçao criteria, defined as spontaneous and recurrent epistaxis and having at least 2 of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive engasertib as an oral capsule QD for 28 weeks.
Drug: Engasertib
Participants will receive matching placebo as an oral capsule QD for 28 weeks.
Drug: Placebo
Engasertib will be administered as oral capsules.
Also known as: VAD044
Placebo will be administered as oral capsules.
Total Number of Epistaxis Events Through Week 28
Time frame: Day 1 through Week 28
Absolute Change from Baseline in Total Duration of Epistaxis at Week 28
Time frame: Baseline and Week 28
Absolute Change from Baseline in Epistaxis Severity Score (ESS) at Week 28
Time frame: Baseline and Week 28
Absolute Change from Baseline in the Nasal Outcome Score for Epistaxis in HHT (NOSE HHT) Score at Week 28
Time frame: Baseline and Week 28
Absolute Change in Red Blood Cell (RBC) Unit Equivalents (RUEs) Received at Week 28
Time frame: Baseline and Week 28
Patient Global Impression of Change (PGIC) Nosebleeds Question at Week 28
Time frame: Week 28
HHT-specific Quality of Life (HHT-QoL) Score at Week 28
Time frame: Week 28
Absolute Change from Baseline in the Intensity-adjusted Duration of Epistaxis per Month at Week 28
Time frame: Baseline and Week 28
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jun 2028, 19 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Belgium, France, Germany, Hungary, Italy, Netherlands, Spain, United Kingdom
Belgium, France, Germany, Hungary, Italy, Netherlands, Spain, United Kingdom
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Engasertib
Telangiectasia, Hereditary Hemorrhagic →
Vaderis Therapeutics AG